Epeius Pharma
Delivery of Therapeutic Proteins into the Central Nervous System
Company Overview
Snapshot
Founded in February 2019 by Prof. Oded Rechavi and Shahar Bracha, Epeius Pharma operates with 1–10 employees. The company has raised $3.5M across one funding round from two investors. In January 2020, FutuRx, in collaboration with Ramot at Tel-Aviv University and Glasgow University, launched Epeius Pharma to advance treatments for complex neurological diseases.
Business overview
Epeius Pharma is a cell and gene therapy company focused on developing biological vehicles for the precise delivery of therapeutic proteins into the central nervous system. Its platform aims to provide an effective and scalable strategy for disease modification in neurodevelopmental and neurological pathologies that could benefit from direct neuron protein replacement treatments, with an initial focus on Rett syndrome. The company operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals within the Pharma & Medical Biotechnology and Drug Delivery categories.
Strategic signal
In January 2020, Epeius Pharma was launched by FutuRx, Ramot at Tel-Aviv University, and Glasgow University to develop treatments for complex neurological diseases. This collaboration signals strong institutional validation and a strategic commitment to addressing significant unmet medical needs in neurodevelopmental and neurological pathologies, leveraging academic research into a commercial venture.
Log in to access full profile ›Company Intelligence Q&A
- When was Epeius Pharma founded?
- Epeius Pharma was founded in February 2019 by Prof. Oded Rechavi and Shahar Bracha.
- What is Epeius Pharma's primary focus?
- Epeius Pharma is developing biological vehicles for the delivery of therapeutic proteins into the central nervous system, initially targeting Rett syndrome.
- Which institutions were involved in the launch of Epeius Pharma?
- In January 2020, FutuRx, Ramot at Tel-Aviv University, and Glasgow University jointly launched Epeius Pharma to develop treatments for complex neurological diseases.
- How much capital has Epeius Pharma raised?
- Epeius Pharma has raised $3.5M across one funding round.
- What is the company's employee count?
- Epeius Pharma currently operates with 1–10 employees.